Manoranjan Panda

This inventor holds 17 USPTO granted patents and 10 published patent applications and 9 EPO patents, primarily in Small Molecule Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No.5) Limited. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Manoranjan Panda. Retrieved from https://idiyas.com/inventor/manoranjan-panda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 10)

% Patents Active = 94.1

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 7.6

ph-index = 1

Forward Citations = 6(Granted Patents)

Location History:

Karnataka, IN (2023)
Bengaluru, IN (2019 - 2024)

Company Filing History:

16 out of 3,745

Bristol-Myers Squibb Compnay

patents

1 out of 45

Viiv Healthcare UK (No.5) Limited

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

KRAS Inhibitors

Heterocyclic PAD4 Inhibitors

Galectin-3 Inhibitors

Tetrahydropyran

Cyclobutanes

Azetidine Compounds

Integrin Inhibitors

ROCK Inhibitors

Substituted Nitrogen Compounds

Bicyclic Heterocyclic Compounds

HIV Replication Inhibitors

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624033 - KRAS inhibitors (2026-05-12),

2. 12473304 - Heterocyclic PAD4 inhibitors (2025-11-18),

3. 12286424 - Small molecule inhibitors of galectin-3 (2025-04-29),

4. 12275720 - Small molecule inhibitors of galectin-3 (2025-04-14),

5. 12269819 - Small molecule inhibitors of Galectin-3 (2025-04-08),

6. 11970511 - Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors (2024-04-30),

7. RE49700 - Substituted nitrogen containing compounds (2023-10-17),

8. 11639353 - Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors (2023-05-02),

9. 11267811 - Small molecule inhibitors of galectin-3 (2022-03-08),

10. 11072626 - Small molecule inhibitors of Galectin-3 (2021-07-27),

11. 11014922 - Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors (2021-05-25),

12. 10851108 - Substituted bicyclic heterocyclic compounds (2020-12-01),

13. 10829501 - Spiroheptane salicylamides and related compounds as inhibitors of ROCK (2020-11-10),

14. 10723723 - Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors (2020-07-28),

15. 10611776 - Spiroheptane salicylamides and related compounds as inhibitors of rock (2020-04-07),

Title: Innovations by Manoranjan Panda in Galectin-3 Research

Introduction

Manoranjan Panda is a prominent inventor based in Bengaluru, India, known for his groundbreaking contributions to pharmaceutical research. With a remarkable portfolio of 15 patents, he has established himself as a leader in developing compounds that inhibit galectin-3, a target of interest in various therapeutic areas.

Latest Patents

Manoranjan Panda's latest innovations include small molecule inhibitors of galectin-3. The patents detail compounds of Formula (I) that demonstrate the ability to inhibit galectin-3, alongside pharmaceutically acceptable salts, compositions that comprise these compounds, and methodologies for using and producing these innovative compounds and compositions. Additional patents focus on compounds of Formula (II), further expanding the toolkit available for therapeutic applications related to galectin-3.

Career Highlights

Panda has built an impressive career through his work with major pharmaceutical companies, including Bristol-Myers Squibb Company and ViiV Healthcare UK Limited. His dedication to advancing the field of medicinal chemistry and developing innovative therapeutic solutions is reflected in his extensive research and development efforts.

Collaborations

Throughout his career, Manoranjan has collaborated with distinguished professionals such as Prasada Rao Jalagam and Alicia Regueiro-Ren. These partnerships have enriched his research endeavors and contributed significantly to the success of his projects.

Conclusion

Manoranjan Panda's contributions to the field of pharmaceutical research, particularly in the development of galectin-3 inhibitors, showcase his expertise and dedication as an inventor. With a total of 15 patents, his innovative work continues to inspire advancements in therapeutics, paving the way for potential breakthroughs in treatments for various diseases.

Profile summary based on public USPTO records.